Prescription Trends for the Antidiabetic Agents Used to Treat Type 2 Diabetes Mellitus in Japan from 2012-2020: a Time-Series Analysis., Iketani Ryo;Imai Shinobu, Biological & pharmaceutical bulletin,
46(4), 2023年,
原著,
査読あり,
DOI:10.1248/bpb.b22-00710 Impact of breakthrough trials on prescription trends of sodium‐glucose cotransporter‐2 inhibitors in Japan: An interrupted time‐series analysis, Ryo Iketani; Shinobu Imai, Journal of Clinical Pharmacy and Therapeutics, 47(11):1796 - 1804, 2022年11月, 原著, 査読あり
Identification of individuals benefiting from the kakaritsuke-yakuzaishi (family pharmacist) system in Japan: a retrospective cohort study using an employment-based health insurance claims database, Ryo Iketani; Keiko Konomura, BMC Health Serv Res, 22(1):682 - 682, 2022年05月, 原著, 査読あり
かかりつけ薬剤師制度の有用性:レセプトデータを用いた後ろ向きコホート研究, 池谷怜; 此村恵子, 医療薬学, 47(9):453 - 463, 2021年09月, 原著, 査読あり
保険薬局において重点的薬学管理を必要とする2型糖尿病患者の特定: レセプトデータを用いた定量的評価, 池谷怜; 此村恵子, 医療薬学, 47(1):10 - 24, 2021年01月, 原著, 査読あり
Efficacy and safety of atypical antipsychotics for psychosis in Parkinson's disease: A systematic review and Bayesian network meta-analysis., Ryo Iketani; Daisuke Furushima; Shinobu Imai; Hiroshi Yamada, Parkinsonism & related disorders, 78:82 - 90, 2020年07月, 原著, 査読あり
Risk stratification for physical morbidity using factors associated with atypical antipsychotic treatment in Parkinson's disease: A retrospective observational study using administrative claims data., Ryo Iketani; Shinobu Imai; Hiromasa Horiguchi; Daisuke Furushima; Kiyohide Fushimi; Hiroshi Yamada, Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 76:189 - 194, 2020年04月, 原著, 査読あり
Prevention of Acute Upper Respiratory Infections by Consumption of Catechins in Healthcare Workers: A Randomized, Placebo-Controlled Trial., Daisuke Furushima; Takuma Nishimura; Norikata Takuma; Ryo Iketani; Tomohito Mizuno; Yuji Matsui; Tohru Yamaguchi; Yu Nakashima; Shinji Yamamoto; Masanobu Hibi; Hiroshi Yamada, Nutrients, 12(1), 2019年12月, 原著, 査読あり
Comparison of the association of risperidone and quetiapine with deteriorating performance in walking and dressing in subjects with Parkinson’s disease: a retrospective cohort study using administrative claims data, Iketani R; Imai S; Horiguchi H; Furushima D; Fushimi K; Yamada H, International Clinical Psychopharmacology, 34(5):234 - 240, 2019年09月, 原著, 査読あり
The Effect of Tea Catechins on Natural Killer Cell Activity in the Elderly: A Pilot Study, IKETANI Ryo; YAMADA Hiroshi; FURUSHIMA Daisuke; NISHIMURA Takuma; HIRAMA Yui; ONISHI Shintaro; KANBARA Hidetoshi; MORI Takuya; OTA Noriyasu; OHNO Yuko, 臨床薬理, 50(4):139 - 145, 2019年, 原著, 査読あり
Apolipoprotein E Gene Polymorphisms Affect the Efficacy of Thiazolidinediones for Alzheimer's Disease: A Systematic Review and Meta-Analysis., Iketani R; Ohno K; Kawasaki Y; Matsumoto K; Yamada H; Kishino S, Biological & pharmaceutical bulletin, 41(7):1017 - 1023, 2018年, 原著, 査読あり
Regional differences in the safety of telaprevir-based triple therapy for chronic hepatitis C in Japan: a retrospective cohort study, R. Iketani; K. Ide; H. Yamada; Y. Kawasaki; N. Masaki, Japanese Journal of Drug Informatics, 2018年, 原著, 査読あり
Comparative Utility of Atypical Antipsychotics for the Treatment of Psychosis in Parkinson's Disease: A Systematic Review and Bayesian Network Meta-analysis, Ryo Iketani; Yohei Kawasaki; Hiroshi Yamada, BIOLOGICAL & PHARMACEUTICAL BULLETIN, 40(11):1976 - 1982, 2017年11月, 原著, 査読あり
Safety Profile of Telaprevir-Based Triple Therapy in Elderly Patients: A Real-World Retrospective Cohort Study, Maiko Akutagawa; Kazuki Ide; Yohei Kawasaki; Mie Yamanaka; Ryo Iketani; Hiroshi Yamada; Naohiko Masaki, BIOLOGICAL & PHARMACEUTICAL BULLETIN, 40(9):1525 - 1529, 2017年09月, 原著, 査読あり
健康食品の利用が関連した被害通報の実態調査―消費者及び医師・薬剤師を対象としたインターネット調査―., 千葉剛; 小林悦子; 佐藤陽子; 井出和希; 池谷怜; 山田浩; 梅垣敬三, 食品衛生学雑誌., 58:234 - 240, 2017年07月, 原著, 査読あり
Risk Factors for Treatment Discontinuation Caused by Adverse Events When Using Telaprevir, Peginterferon, and Ribavirin to Treat Chronic Hepatitis C: A Real-World Retrospective Cohort Study, Kazuki Ide; Yohei Kawasaki; Ryo Iketani; Naohiko Masaki, BIOLOGICAL & PHARMACEUTICAL BULLETIN, 40(5):645 - 649, 2017年05月, 原著, 査読あり
The Safety Profile of Telaprevir-Based Triple Therapy in Clinical Practice: A Retrospective Cohort Study, Ryo Iketani; Kazuki Ide; Hiroshi Yamada; Yohei Kawasaki; Naohiko Masaki, BIOLOGICAL & PHARMACEUTICAL BULLETIN, 40(5):687 - 692, 2017年05月, 原著, 査読あり